Related Experiment Videos
[Phase II study of recombinant human leukocyte A interferon on urogenital cancer patients]
Abstract:
A phase II study on recombinant human leukocyte A interferon (rIFN-alpha A) was carried out in 30 patients with urogenital cancers. Each patient received rIFN-alpha A by i.m. injection every day for at least 4 weeks. The initial daily dose was 3 X 10(6) U, being escalated at intervals of 3 days or more up to 50 X 10(6) U. The results are summarized as follows: In aged patients, the daily dose appropriate for everyday i.m. injection was considered to be 9 X 10(6) U or below, judging from the adverse reactions observed. According to Koyama and Saito's response criteria, partial response (PR) and minor response (MR) were obtained, respectively, in 3 and 1 out of 12 patients with renal cell carcinoma, while PR was seen in 1 out of 9 with urothelial cancer. No response was observed in patients with testicular cancer and in those with prostatic cancer. Various kinds of adverse reactions were recognized and each patient showed one reaction or more. Fever, fatigue, leukopenia, anemia, thrombocytopenia and elevation of GOT and GPT were observed relatively frequently. Among these, fatigue and thrombocytopenia were regarded as dose limiting factors.
Insights
Recombinant human leukocyte A interferon (rIFN-alpha A) showed limited efficacy in urogenital cancers. Doses above 9 million units daily were limited by adverse effects like fatigue and thrombocytopenia in elderly patients.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Context:
- Urogenital cancers represent a significant global health challenge.
- Interferon-alpha has been explored as a therapeutic agent for various cancers.
- Phase II clinical trials are crucial for evaluating novel cancer treatments.
Purpose:
- To assess the efficacy and safety of recombinant human leukocyte A interferon (rIFN-alpha A) in patients with urogenital cancers.
- To determine appropriate dosing strategies for rIFN-alpha A based on patient age and observed adverse reactions.
- To evaluate treatment response according to established criteria in different subtypes of urogenital malignancies.
Summary:
- A phase II study administered daily intramuscular rIFN-alpha A to 30 patients with urogenital cancers, escalating doses up to 50 million units.
- Adverse reactions, including fever, fatigue, leukopenia, anemia, thrombocytopenia, and elevated liver enzymes, were frequent, with fatigue and thrombocytopenia identified as dose-limiting.
- In elderly patients, doses of 9 million units or lower were deemed appropriate due to observed side effects.
- Partial responses were noted in 3/12 renal cell carcinoma patients and 1/9 urothelial cancer patients; no responses were seen in testicular or prostate cancer patients.
Impact:
- Identifies potential dose limitations for rIFN-alpha A in urogenital cancer treatment, particularly in elderly populations.
- Provides data on the efficacy of rIFN-alpha A in specific urogenital cancer subtypes, suggesting limited utility in some.
- Highlights the importance of monitoring for specific adverse events like fatigue and thrombocytopenia during interferon therapy.